Topic Editors

Department of Molecular Medicine and Medical Biotechnology, Federico II Faculty of Naples, 80138 Napoli, Italy
Dr. Renata Grifantini
Head Translational Research Unit, Istituto Nazionale di Genetica Molecolare (INGM), Milano, Italy

Anti-Tumor Immune Responses 2.0

Abstract submission deadline
30 June 2024
Manuscript submission deadline
31 August 2024
Viewed by
1127

Topic Information

Dear Colleagues,

It remains unclear how and when, during multi-step tumor progression via clonal selection, cancer cells are selected for their high mutational burden, as well as how the immune system is first alerted to their presence and begins its initial, often unsuccessful, attempts at eliminating them. At present, it is impossible to say which of the dozens of immunotherapy strategies under development will become the precursors of anti-cancer treatments that will prove to be vastly more effective than those developed to date and that will generate robust, durable responses for the majority of patients receiving treatment. For example, advances in molecular genetics, biochemistry, virus biology, cellular and system biology, and cellular immunology have recently converged with discoveries in drugs and antibodies to generate novel, potentially powerful ways to harness the immune response to eradicate human tumors. At this time, the action of the immune system has improved two types of attacks against infectious agents or cells targeted for destruction or neutralization. These involve humoral and cellular immunity, as some types of cells, particularly macrophages and NK cells, have an innate ability to recognize cells that should be destroyed. In this issue, we would like to discuss the frontiers in this area of research concerning cancer cell types where these phenomena have been proven to be positively active at the level of hematopoietic malignancies and, most importantly, in solid tumors with advanced immune therapies. Examples of instances where these strategies fail are of great value for better understanding how cancer cells evade this immune mechanism using the most recent genome biology technologies to determine which other genes/proteins/pathways are involved in these coordinated, interconnecting actions.

Prof. Dr. Massimo Zollo
Dr. Renata Grifantini
Topic Editors

Keywords

  • genetics
  • biochemistry
  • virology
  • system biology
  • immune evasion
  • immune cells
  • immune drugs
  • immune antibodies
  • signaling pathways
  • immune therapies
  • antitumor vaccines

Participating Journals

Journal Name Impact Factor CiteScore Launched Year First Decision (median) APC
Antibodies
antibodies
4.7 9.6 2012 17.7 Days CHF 1800 Submit
Cancers
cancers
5.2 7.4 2009 17.9 Days CHF 2900 Submit
Immuno
immuno
- - 2021 20.7 Days CHF 1000 Submit
International Journal of Molecular Sciences
ijms
5.6 7.8 2000 16.3 Days CHF 2900 Submit
Vaccines
vaccines
7.8 7.0 2013 19.2 Days CHF 2700 Submit

Preprints.org is a multidiscipline platform providing preprint service that is dedicated to sharing your research from the start and empowering your research journey.

MDPI Topics is cooperating with Preprints.org and has built a direct connection between MDPI journals and Preprints.org. Authors are encouraged to enjoy the benefits by posting a preprint at Preprints.org prior to publication:

  1. Immediately share your ideas ahead of publication and establish your research priority;
  2. Protect your idea from being stolen with this time-stamped preprint article;
  3. Enhance the exposure and impact of your research;
  4. Receive feedback from your peers in advance;
  5. Have it indexed in Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Published Papers (1 paper)

Order results
Result details
Journals
Select all
Export citation of selected articles as:
20 pages, 2300 KiB  
Review
The Role of Tumor Metabolic Reprogramming in Tumor Immunity
Int. J. Mol. Sci. 2023, 24(24), 17422; https://doi.org/10.3390/ijms242417422 - 13 Dec 2023
Cited by 1 | Viewed by 720
Abstract
The occurrence and development of tumors require the metabolic reprogramming of cancer cells, namely the alteration of flux in an autonomous manner via various metabolic pathways to meet increased bioenergetic and biosynthetic demands. Tumor cells consume large quantities of nutrients and produce related [...] Read more.
The occurrence and development of tumors require the metabolic reprogramming of cancer cells, namely the alteration of flux in an autonomous manner via various metabolic pathways to meet increased bioenergetic and biosynthetic demands. Tumor cells consume large quantities of nutrients and produce related metabolites via their metabolism; this leads to the remodeling of the tumor microenvironment (TME) to better support tumor growth. During TME remodeling, the immune cell metabolism and antitumor immune activity are affected. This further leads to the escape of tumor cells from immune surveillance and therefore to abnormal proliferation. This review summarizes the regulatory functions associated with the abnormal biosynthesis and activity of metabolic signaling molecules during the process of tumor metabolic reprogramming. In addition, we provide a comprehensive description of the competition between immune cells and tumor cells for nutrients in the TME, as well as the metabolites required for tumor metabolism, the metabolic signaling pathways involved, and the functionality of the immune cells. Finally, we summarize current research targeted at the development of tumor immunotherapy. We aim to provide new concepts for future investigations of the mechanisms underlying the metabolic reprogramming of tumors and explore the association of these mechanisms with tumor immunity. Full article
(This article belongs to the Topic Anti-Tumor Immune Responses 2.0)
Show Figures

Figure 1

Back to TopTop